CHEMICALS SUMMARY PAGE

Naproxen

Summary Information
Classification Chemicals / Complex Chemical Agents / Type:

(This chemicals section is currently predominantly used in Wildpro to link different data types and demonstrate inter-relationships. It does not contain detailed information on the chemical itself.)

Alternative Names --
Notes Information in this page has been entered to support the current volumes of Wildpro and further information will be added as new volumes are completed. This page is not intended to substitute for the manufacturer's data sheet and the information is not yet complete for all species, or for all contra-indications etc.

CAUTION: Before any pharmaceutical product is used, the manufacturer's data sheet, containing information on uses, dosage and administration, contra-indications, warnings etc., should always be consulted. It is important to remember that licensing of pharmaceutical products for use in a particular species/condition, as well as mandatory meat and milk withdrawal times for food-producing animals, varies between countries and changes with time. Withdrawal times also may vary between different pharmaceutical formulations and depending on route of administration. In the EU, the prescription cascade must be followed (see LCofC1.2H and W564.Apr05.w1); note that specific restrictions apply for food-producing animals. In the USA, FARAD may be consulted regarding residues and meat and milk withdrawal times.

  • NSAID. (B553.21.w21)
  • In horses, bioavailability about 50% in horses following oral administration in a granular form, with peak plasma concentrations at 2-3 hours following oral administartion of 10 mg/kg and 46 hours elimination half-life from plasma. Relatively wide safety margin in horses; no toxicity after administration of three times recommended dose for six weeks. Particularly effective in the treatment of soft tissue inflammation. (B553.21.w21)
  • In dogs, 68-100%bioavailability after oral administration. 99% serum protein bound, and an elimination half-life of 45-92 hours, probably due to extensive enterohepatic recirculation. A loading dose should be given, with administration once daily. Doses of 5 mg/kg result in gastrointestinal toxicity. (B553.21.w21)
  • In humans, elimination half-life following intravenous injection 12-15 hours. (B553.21.w21)
  • Used in humans in the treatment of pain and inflammation in rheumatic disease. In humans, good efficacy and low incidence of side-effects. (W769.Jun2012.w1)
Administration
  • In adult humans:
    • For rheumatic disease, 0.5 - 1.0 g daily in one or two divided doses. (W769.Jun2012.w1)
    • In treatment of acute musculoskeletal disorders, and dysmenorrhea, initially 500 mg then 250 mg every 6-8 hours as required, maximum 1.25 g per day after the first day. (W769.Jun2012.w1)
    • In the treatment of gout, initially 750 mg then 150 mg every eight hours until the attach has ceased. (W769.Jun2012.w1)

Great Apes

Return to Top of Page